Characteristics of our hypoxemic COVID-19 pneumonia patients receiving corticosteroids and mortality-associated factors

Basit Öğe Kaydı
dc.authoridÖzdemir, Özer/0000-0002-8884-0682
dc.authoridSöyler, Yasemin/0000-0002-0507-0767
dc.authoridsatici, celal/0000-0002-5457-9551
dc.authoridAydemir, Yusuf/0000-0003-2479-2949
dc.authorwosidÖzdemir, Özer/GQZ-6473-2022
dc.authorwosidYıldırım, Fatma/AET-5783-2022
dc.authorwosidSöyler, Yasemin/AAF-8533-2021
dc.contributor.authorŞengül, Aysun
dc.contributor.authorMutlu, Pinar
dc.contributor.authorÖzdemir, Özer
dc.contributor.authorSatıcı, Celal
dc.contributor.authorTuran, Muzaffer Onur
dc.contributor.authorArslan, Sertaç
dc.contributor.authorOğan, Nalan
dc.date.accessioned2023-07-26T11:50:53Z
dc.date.available2023-07-26T11:50:53Z
dc.date.issued2022
dc.departmentDÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göğüs Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractBackground COVID-19 is a disease associated with diffuse lung injury that has no proven effective treatment yet. It is thought that glucocorticoids may reduce inflammation-mediated lung injury, disease progression, and mortality. We aimed to evaluate our patient's characteristics and treatment outcomes who received corticosteroids for COVID-19 pneumonia. Methods We conducted a multicenter retrospective study and reviewed 517 patients admitted due to COVID-19 pneumonia who were hypoxemic and administered steroids regarding demographic, laboratory, and radiological characteristics, treatment response, and mortality-associated factors. Results Of our 517 patients with COVID-19 pneumonia who were hypoxemic and received corticosteroids, the mortality rate was 24.4% (n = 126). The evaluation of mortality-associated factors revealed that age, comorbidities, a CURB-65 score of >= 2, higher SOFA scores, presence of MAS, high doses of steroids, type of steroids, COVID-19 treatment, stay in the intensive care unit, high levels of d-dimer, CRP, ferritin, and troponin, and renal dysfunction were associated with mortality. Conclusion Due to high starting and average steroid doses are more associated with mortality, high-dose steroid administration should be avoided. We believe that knowing the factors associated with mortality in these cases is essential for close follow-up. The use of CURB-65 and SOFA scores can predict prognosis in COVID-19 pneumonia.en_US
dc.identifier.doi10.1080/17476348.2022.2102480
dc.identifier.endpage958en_US
dc.identifier.issn1747-6348
dc.identifier.issn1747-6356
dc.identifier.issue8en_US
dc.identifier.pmid35839345en_US
dc.identifier.scopus2-s2.0-85135114550en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage953en_US
dc.identifier.urihttps://doi.org/10.1080/17476348.2022.2102480
dc.identifier.urihttps://hdl.handle.net/20.500.12684/12448
dc.identifier.volume16en_US
dc.identifier.wosWOS:000831157700001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorGülhan, Pınar Yıldız
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofExpert Review of Respiratory Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz$2023V1Guncelleme$en_US
dc.subjectCovid-19; Corticosteroid; Hypoxemia; Mortality; Prognosisen_US
dc.subjectRespiratory-Distress-Syndrome; Dexamethasone; Severityen_US
dc.titleCharacteristics of our hypoxemic COVID-19 pneumonia patients receiving corticosteroids and mortality-associated factorsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
12448.pdf
Boyut:
242.81 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu